Cytotoxicity of Conjugates of 188Re-Labeled Dendrimers and Monoclonal Antibodies Anti-ICO-25 (MUC1) and Anti-ICO-80 (CD5) Against SKOV-3 (Ovary Cancer) and Jurkat Tumor Cell Lines (T-Lymphoblstic Lymphoma)

详细

Targeted radioimmunotherapy is a promising approach to radiotherapy. Tumor-specific compounds were synthesized using monoclonal antibodies anti-ICO-25 (MUC1) and anti-ICO-80 (CD5) labeled with the therapeutic radioisotope ¹⁸⁸Re. The specificity of the conjugates was demonstrated in vitro using SKOV-3 (ovary cancer) and Jurkat tumor cell lines (T-lymphoblastic lymphoma), which are known to have membrane surface receptors specific for the corresponding antibodies. Short-term survival tests revealed 90-93% death of tumor cells, indicating the proposed conjugates were promising for targeted delivery of diagnostic and therapeutic cancer drugs.